Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients.
Sophie Alberdine KurkPetra PeetersRebecca StellatoB DorresteijnPim de JongMarion JourdanGeert-Jan CreemersFrans ErdkampFelix de JonghPeter KintLieke SimkensBea TanisManuel Tjin-A-TonAnkie Van Der VeldenCornelis PuntMiriam KoopmanAnne MayPublished in: Journal of cachexia, sarcopenia and muscle (2019)
In this large longitudinal study in metastatic colorectal cancer patients during palliative systemic treatment, sarcopenia and/or muscle loss was associated with an increased risk of DLTs. BMI was not associated with DLTs and could not detect sarcopenia or SMI loss. Prospective (randomized) studies should reveal whether normalizing chemotherapeutic doses to muscle mass or muscle mass preservation (by exercise and nutritional interventions) increases chemotherapeutic tolerance and improves survival.
Keyphrases
- skeletal muscle
- metastatic colorectal cancer
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- palliative care
- type diabetes
- gene expression
- insulin resistance
- open label
- dna methylation
- double blind
- metabolic syndrome
- single cell
- patient reported
- drug induced
- placebo controlled
- smoking cessation
- replacement therapy
- case control
- weight gain